Review



polyclonal goat anti mouse il 33 antibody  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    R&D Systems polyclonal goat anti mouse il 33 antibody
    <t>IL-33</t> <t>is</t> not expressed by circulating platelets or MKs. (A-B) Representative immunofluorescence images showing nonspecific IL-33 staining in bone marrow (BM)–derived MKs enriched on BSA gradient (A) and platelet-rich plasma (PRP) (B) from WT and IL-33KO mice. (C) Flow-cytometric detection of IL-33 nonspecific signal in blood platelets from WT and IL-33KO mice (PRP), using an isotype control as a negative reference. (D) Western blot analysis of IL-33 expression in platelets and MK-enriched BM cells, with total lung lysates from WT and IL-33 KO mice used as positive and negative controls, respectively. Following quantification, an equal amount of protein (20 μg) was loaded in each lane. (E) IL-33 promoter activity in total BM cells, blood platelets, and BM MK from IL-33–Citrine reporter mice assessed by flow cytometry. (F) Identification of Citrine + cells as stromal cells (CD41 − CD45 − ) in Citrine reporter mice (Citrine +/+ ) by flow cytometry. Panels A-D used a polyclonal goat anti-mouse IL-33 antibody. FL, full length; IF, immunofluorescence; KO, knockout; mIL, mouse interleukin; SSC-A, side scatter.
    Polyclonal Goat Anti Mouse Il 33 Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 253 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/polyclonal goat anti mouse il 33 antibody/product/R&D Systems
    Average 94 stars, based on 253 article reviews
    polyclonal goat anti mouse il 33 antibody - by Bioz Stars, 2026-05
    94/100 stars

    Images

    1) Product Images from "The alarmin interleukin-33 modulates platelet proteome, function, and biogenesis"

    Article Title: The alarmin interleukin-33 modulates platelet proteome, function, and biogenesis

    Journal: Blood Advances

    doi: 10.1182/bloodadvances.2025018363

    IL-33 is not expressed by circulating platelets or MKs. (A-B) Representative immunofluorescence images showing nonspecific IL-33 staining in bone marrow (BM)–derived MKs enriched on BSA gradient (A) and platelet-rich plasma (PRP) (B) from WT and IL-33KO mice. (C) Flow-cytometric detection of IL-33 nonspecific signal in blood platelets from WT and IL-33KO mice (PRP), using an isotype control as a negative reference. (D) Western blot analysis of IL-33 expression in platelets and MK-enriched BM cells, with total lung lysates from WT and IL-33 KO mice used as positive and negative controls, respectively. Following quantification, an equal amount of protein (20 μg) was loaded in each lane. (E) IL-33 promoter activity in total BM cells, blood platelets, and BM MK from IL-33–Citrine reporter mice assessed by flow cytometry. (F) Identification of Citrine + cells as stromal cells (CD41 − CD45 − ) in Citrine reporter mice (Citrine +/+ ) by flow cytometry. Panels A-D used a polyclonal goat anti-mouse IL-33 antibody. FL, full length; IF, immunofluorescence; KO, knockout; mIL, mouse interleukin; SSC-A, side scatter.
    Figure Legend Snippet: IL-33 is not expressed by circulating platelets or MKs. (A-B) Representative immunofluorescence images showing nonspecific IL-33 staining in bone marrow (BM)–derived MKs enriched on BSA gradient (A) and platelet-rich plasma (PRP) (B) from WT and IL-33KO mice. (C) Flow-cytometric detection of IL-33 nonspecific signal in blood platelets from WT and IL-33KO mice (PRP), using an isotype control as a negative reference. (D) Western blot analysis of IL-33 expression in platelets and MK-enriched BM cells, with total lung lysates from WT and IL-33 KO mice used as positive and negative controls, respectively. Following quantification, an equal amount of protein (20 μg) was loaded in each lane. (E) IL-33 promoter activity in total BM cells, blood platelets, and BM MK from IL-33–Citrine reporter mice assessed by flow cytometry. (F) Identification of Citrine + cells as stromal cells (CD41 − CD45 − ) in Citrine reporter mice (Citrine +/+ ) by flow cytometry. Panels A-D used a polyclonal goat anti-mouse IL-33 antibody. FL, full length; IF, immunofluorescence; KO, knockout; mIL, mouse interleukin; SSC-A, side scatter.

    Techniques Used: Immunofluorescence, Staining, Derivative Assay, Clinical Proteomics, Control, Western Blot, Expressing, Activity Assay, Flow Cytometry, Knock-Out

    IL-33 deficiency alters the platelet proteome. (A) Proteomic profiling of sorted platelets from WT and IL-33KO mice. (B) Volcano plot comparing IL-33KO and WT platelet proteomes. The x-axis shows log fold change (IL-33KO/WT), and the y-axis shows −log( P -value). Proteins upregulated in IL-33KO platelets are highlighted in blue; downregulated proteins in gray. (C) Number of proteins detected and significantly altered ( P < .03, fold change > 0.2). (D,F) Gene Ontology (GO) analysis of enriched biological processes among upregulated (D) and downregulated (F) proteins ( https://geneontology.org ). (E,G) Heat maps of the top 20 most abundant upregulated (E) and downregulated (G) proteins. Data were obtained from n = 5 mice per group. KO, knockout. Figure created with biorender.com . Blanchard L. (2026) https://BioRender.com/b78qj95 .
    Figure Legend Snippet: IL-33 deficiency alters the platelet proteome. (A) Proteomic profiling of sorted platelets from WT and IL-33KO mice. (B) Volcano plot comparing IL-33KO and WT platelet proteomes. The x-axis shows log fold change (IL-33KO/WT), and the y-axis shows −log( P -value). Proteins upregulated in IL-33KO platelets are highlighted in blue; downregulated proteins in gray. (C) Number of proteins detected and significantly altered ( P < .03, fold change > 0.2). (D,F) Gene Ontology (GO) analysis of enriched biological processes among upregulated (D) and downregulated (F) proteins ( https://geneontology.org ). (E,G) Heat maps of the top 20 most abundant upregulated (E) and downregulated (G) proteins. Data were obtained from n = 5 mice per group. KO, knockout. Figure created with biorender.com . Blanchard L. (2026) https://BioRender.com/b78qj95 .

    Techniques Used: Knock-Out

    IL-33 deficiency impairs platelets adhesion to ECM components. (A) Schematic and (B) analysis of platelet adhesion assays to soluble fibrinogen, with or without ADP (1μM), assessed by flow cytometry. PRP from WT and IL-33 KO mice was analyzed, and results are expressed as a ratio relative to the WT mean. Data were obtained from n = 11 mice per group across 3 independent experiments. (C) Schematic of platelet spreading assays on fixed substrates, analyzed by immunofluorescence in WT and IL-33 KO platelets. Representative images and quantitative analyses of adherent and spreading PRP from WT or IL-33 KO mice on (D) fibrinogen, (E) podoplanin, and (F) laminin at 5 and 15 minutes following ADP (1μM) stimulation. Platelets were stained with CD41-APC. Data were obtained from n = 11 mice per group across 3 independent experiments, except for the laminin spreading assay, which was performed on n = 5 mice in a single experiment. (G-H) Platelet spreading assays without ADP stimulation on fibrinogen (G) and podoplanin (H) at 5 and 15 minutes (n = 7 mice per group per experiment). Statistical analyses were performed using t tests (D-F) and 2-way analysis of variance (ANOVA) with Sidak multiple comparisons test (B). Scale bar, 20 μm. Statistical analysis was conducted using t tests; # P < .05; ## P < .01; ### P < .001; #### P < .0001. IF, immunofluorescence. Figure created with biorender.com . Blanchard L. (2026) https://BioRender.com/z523pur .
    Figure Legend Snippet: IL-33 deficiency impairs platelets adhesion to ECM components. (A) Schematic and (B) analysis of platelet adhesion assays to soluble fibrinogen, with or without ADP (1μM), assessed by flow cytometry. PRP from WT and IL-33 KO mice was analyzed, and results are expressed as a ratio relative to the WT mean. Data were obtained from n = 11 mice per group across 3 independent experiments. (C) Schematic of platelet spreading assays on fixed substrates, analyzed by immunofluorescence in WT and IL-33 KO platelets. Representative images and quantitative analyses of adherent and spreading PRP from WT or IL-33 KO mice on (D) fibrinogen, (E) podoplanin, and (F) laminin at 5 and 15 minutes following ADP (1μM) stimulation. Platelets were stained with CD41-APC. Data were obtained from n = 11 mice per group across 3 independent experiments, except for the laminin spreading assay, which was performed on n = 5 mice in a single experiment. (G-H) Platelet spreading assays without ADP stimulation on fibrinogen (G) and podoplanin (H) at 5 and 15 minutes (n = 7 mice per group per experiment). Statistical analyses were performed using t tests (D-F) and 2-way analysis of variance (ANOVA) with Sidak multiple comparisons test (B). Scale bar, 20 μm. Statistical analysis was conducted using t tests; # P < .05; ## P < .01; ### P < .001; #### P < .0001. IF, immunofluorescence. Figure created with biorender.com . Blanchard L. (2026) https://BioRender.com/z523pur .

    Techniques Used: Flow Cytometry, Immunofluorescence, Staining

    IL-33 deficiency reduces thrombus formation under high shear stress. (A) Schematic representation of the thrombus formation assay on collagen during arterial flow of whole blood from WT or IL-33 KO mice. (B) Representative images and quantitative analysis of thrombus volume, expressed as a percentage relative to the WT mean, formed on collagen under physiological arterial shear rate (1500 s ˗1 ) using whole blood from WT or IL-33 KO mice. (C) Representative images and quantitative analysis of thrombus volume, expressed as a percentage relative to the WT mean, formed on collagen under pathological arterial shear rate (3000 s ˗1 ) using whole blood from WT or IL-33 KO mice. Data are representative of 3 independent experiments (n = 4-5 mice/group). Statistical analysis was performed using 2-way ANOVA with Sidak multiple comparisons test, # P < .05. Investigators were blinded to genotype during the thrombus formation assay. Figure created with biorender.com . Blanchard L. (2026) https://BioRender.com/tt7i113 .
    Figure Legend Snippet: IL-33 deficiency reduces thrombus formation under high shear stress. (A) Schematic representation of the thrombus formation assay on collagen during arterial flow of whole blood from WT or IL-33 KO mice. (B) Representative images and quantitative analysis of thrombus volume, expressed as a percentage relative to the WT mean, formed on collagen under physiological arterial shear rate (1500 s ˗1 ) using whole blood from WT or IL-33 KO mice. (C) Representative images and quantitative analysis of thrombus volume, expressed as a percentage relative to the WT mean, formed on collagen under pathological arterial shear rate (3000 s ˗1 ) using whole blood from WT or IL-33 KO mice. Data are representative of 3 independent experiments (n = 4-5 mice/group). Statistical analysis was performed using 2-way ANOVA with Sidak multiple comparisons test, # P < .05. Investigators were blinded to genotype during the thrombus formation assay. Figure created with biorender.com . Blanchard L. (2026) https://BioRender.com/tt7i113 .

    Techniques Used: Shear, Tube Formation Assay

    IL-33 treatment in vivo modifies platelet morphology and activation, expands the MK-biased LT-HSC pool, and enhances platelet release within lung capillaries. (A) Schematic overview of the IL-33 treatment protocol: WT mice received 3 intranasal doses of recombinant human IL-33 or PBS. (B) Flow cytometry analysis of platelet morphology in WT mice following IL-33 or PBS treatment. (C) Quantification of platelet counts by flow cytometry in IL-33- or PBS-treated WT mice. Data are from n = 14 mice per group, collected across 3 independent experiments. (D) Flow cytometry assessment of platelet degranulation, measuring alpha granule (P-selectin) and dense granule (CD63) expression after IL-33 or PBS administration. (E) Plasma levels of sCD40L, measured by ELISA in IL-33–treated or PBS-treated WT mice. (D-E) Data are from n = 8 to 9 mice per group, collected across 2 independent experiments. (F) Quantification of BM LT-HSC, separated into CD41 ˗ (canonical) and CD41 + (MK-biased) populations, shown as a percentage of LSK cells. Data are obtained from n = 22 mice per group, collected across 5 independent experiments. (G) Lung intravital microscopy was performed in PF4-mTmG mice treated with IL-33 or PBS, 24 hours after the first (IL-33 1×) or third (IL-33 3×) administration to assess MKs/proplatelets generating platelets. (H) Representative time-lapse intravital lung microscopy images showing PF4 + small proplatelets and large proplatelet/MK structures releasing platelets within pulmonary capillaries. Scale bar, 50 μm. (I-J) Quantification of proplatelet structures producing platelets per hour per ROI in the lung, categorized as small (<200 platelet volume equivalent), medium (200-1000 platelets), and large (>1000 platelets). (K) Total platelet release per hour across the entire lung. Statistical analysis was performed using t test; # P < .05, ## P < .01. A total of n = 5 to 21 videos were analyzed, collected from 3 to 11 mice per group across 5 independent experiments. ns, not significant. Figure created with biorender.com . Blanchard L. (2026) https://BioRender.com/qdgtyov .
    Figure Legend Snippet: IL-33 treatment in vivo modifies platelet morphology and activation, expands the MK-biased LT-HSC pool, and enhances platelet release within lung capillaries. (A) Schematic overview of the IL-33 treatment protocol: WT mice received 3 intranasal doses of recombinant human IL-33 or PBS. (B) Flow cytometry analysis of platelet morphology in WT mice following IL-33 or PBS treatment. (C) Quantification of platelet counts by flow cytometry in IL-33- or PBS-treated WT mice. Data are from n = 14 mice per group, collected across 3 independent experiments. (D) Flow cytometry assessment of platelet degranulation, measuring alpha granule (P-selectin) and dense granule (CD63) expression after IL-33 or PBS administration. (E) Plasma levels of sCD40L, measured by ELISA in IL-33–treated or PBS-treated WT mice. (D-E) Data are from n = 8 to 9 mice per group, collected across 2 independent experiments. (F) Quantification of BM LT-HSC, separated into CD41 ˗ (canonical) and CD41 + (MK-biased) populations, shown as a percentage of LSK cells. Data are obtained from n = 22 mice per group, collected across 5 independent experiments. (G) Lung intravital microscopy was performed in PF4-mTmG mice treated with IL-33 or PBS, 24 hours after the first (IL-33 1×) or third (IL-33 3×) administration to assess MKs/proplatelets generating platelets. (H) Representative time-lapse intravital lung microscopy images showing PF4 + small proplatelets and large proplatelet/MK structures releasing platelets within pulmonary capillaries. Scale bar, 50 μm. (I-J) Quantification of proplatelet structures producing platelets per hour per ROI in the lung, categorized as small (<200 platelet volume equivalent), medium (200-1000 platelets), and large (>1000 platelets). (K) Total platelet release per hour across the entire lung. Statistical analysis was performed using t test; # P < .05, ## P < .01. A total of n = 5 to 21 videos were analyzed, collected from 3 to 11 mice per group across 5 independent experiments. ns, not significant. Figure created with biorender.com . Blanchard L. (2026) https://BioRender.com/qdgtyov .

    Techniques Used: In Vivo, Activation Assay, Recombinant, Flow Cytometry, Expressing, Clinical Proteomics, Enzyme-linked Immunosorbent Assay, Intravital Microscopy, Microscopy

    IL-33 in vivo treatment alters platelet proteome, modulating inflammatory and coagulation-related pathways. (A) Proteomic profiling of sorted platelets from WT mice treated with PBS or recombinant (rIL-33). (B) Volcano plot comparing human rIL-33 and PBS-treated mice platelet proteomes. The x-axis shows log fold change (IL-33KO/WT), and the y-axis shows ˗log( P -value). Proteins upregulated in IL-33 treated mice platelets are highlighted in orange; downregulated proteins in gray. (C) Number of proteins detected and significantly altered ( P < .03, fold change > 0.2). (D,F) Gene Ontology (GO) analysis of enriched biological processes among upregulated (D) and downregulated (F) proteins ( https://geneontology.org ). (E,G) Heat maps of the top 20 most abundant upregulated (E) and downregulated (G) proteins. Data represent n = 10 mice per group, collected from 2 independent experiments. Figure created with biorender.com . Blanchard L. (2026) https://BioRender.com/og48c3y .
    Figure Legend Snippet: IL-33 in vivo treatment alters platelet proteome, modulating inflammatory and coagulation-related pathways. (A) Proteomic profiling of sorted platelets from WT mice treated with PBS or recombinant (rIL-33). (B) Volcano plot comparing human rIL-33 and PBS-treated mice platelet proteomes. The x-axis shows log fold change (IL-33KO/WT), and the y-axis shows ˗log( P -value). Proteins upregulated in IL-33 treated mice platelets are highlighted in orange; downregulated proteins in gray. (C) Number of proteins detected and significantly altered ( P < .03, fold change > 0.2). (D,F) Gene Ontology (GO) analysis of enriched biological processes among upregulated (D) and downregulated (F) proteins ( https://geneontology.org ). (E,G) Heat maps of the top 20 most abundant upregulated (E) and downregulated (G) proteins. Data represent n = 10 mice per group, collected from 2 independent experiments. Figure created with biorender.com . Blanchard L. (2026) https://BioRender.com/og48c3y .

    Techniques Used: In Vivo, Coagulation, Recombinant



    Similar Products

    94
    R&D Systems polyclonal goat anti mouse il 33 antibody
    <t>IL-33</t> <t>is</t> not expressed by circulating platelets or MKs. (A-B) Representative immunofluorescence images showing nonspecific IL-33 staining in bone marrow (BM)–derived MKs enriched on BSA gradient (A) and platelet-rich plasma (PRP) (B) from WT and IL-33KO mice. (C) Flow-cytometric detection of IL-33 nonspecific signal in blood platelets from WT and IL-33KO mice (PRP), using an isotype control as a negative reference. (D) Western blot analysis of IL-33 expression in platelets and MK-enriched BM cells, with total lung lysates from WT and IL-33 KO mice used as positive and negative controls, respectively. Following quantification, an equal amount of protein (20 μg) was loaded in each lane. (E) IL-33 promoter activity in total BM cells, blood platelets, and BM MK from IL-33–Citrine reporter mice assessed by flow cytometry. (F) Identification of Citrine + cells as stromal cells (CD41 − CD45 − ) in Citrine reporter mice (Citrine +/+ ) by flow cytometry. Panels A-D used a polyclonal goat anti-mouse IL-33 antibody. FL, full length; IF, immunofluorescence; KO, knockout; mIL, mouse interleukin; SSC-A, side scatter.
    Polyclonal Goat Anti Mouse Il 33 Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/polyclonal goat anti mouse il 33 antibody/product/R&D Systems
    Average 94 stars, based on 1 article reviews
    polyclonal goat anti mouse il 33 antibody - by Bioz Stars, 2026-05
    94/100 stars
      Buy from Supplier

    94
    R&D Systems polyclonal goat anti il 33 r d systems
    <t>IL-33</t> <t>is</t> not expressed by circulating platelets or MKs. (A-B) Representative immunofluorescence images showing nonspecific IL-33 staining in bone marrow (BM)–derived MKs enriched on BSA gradient (A) and platelet-rich plasma (PRP) (B) from WT and IL-33KO mice. (C) Flow-cytometric detection of IL-33 nonspecific signal in blood platelets from WT and IL-33KO mice (PRP), using an isotype control as a negative reference. (D) Western blot analysis of IL-33 expression in platelets and MK-enriched BM cells, with total lung lysates from WT and IL-33 KO mice used as positive and negative controls, respectively. Following quantification, an equal amount of protein (20 μg) was loaded in each lane. (E) IL-33 promoter activity in total BM cells, blood platelets, and BM MK from IL-33–Citrine reporter mice assessed by flow cytometry. (F) Identification of Citrine + cells as stromal cells (CD41 − CD45 − ) in Citrine reporter mice (Citrine +/+ ) by flow cytometry. Panels A-D used a polyclonal goat anti-mouse IL-33 antibody. FL, full length; IF, immunofluorescence; KO, knockout; mIL, mouse interleukin; SSC-A, side scatter.
    Polyclonal Goat Anti Il 33 R D Systems, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/polyclonal goat anti il 33 r d systems/product/R&D Systems
    Average 94 stars, based on 1 article reviews
    polyclonal goat anti il 33 r d systems - by Bioz Stars, 2026-05
    94/100 stars
      Buy from Supplier

    94
    R&D Systems polyclonal goat
    <t>IL-33</t> <t>is</t> not expressed by circulating platelets or MKs. (A-B) Representative immunofluorescence images showing nonspecific IL-33 staining in bone marrow (BM)–derived MKs enriched on BSA gradient (A) and platelet-rich plasma (PRP) (B) from WT and IL-33KO mice. (C) Flow-cytometric detection of IL-33 nonspecific signal in blood platelets from WT and IL-33KO mice (PRP), using an isotype control as a negative reference. (D) Western blot analysis of IL-33 expression in platelets and MK-enriched BM cells, with total lung lysates from WT and IL-33 KO mice used as positive and negative controls, respectively. Following quantification, an equal amount of protein (20 μg) was loaded in each lane. (E) IL-33 promoter activity in total BM cells, blood platelets, and BM MK from IL-33–Citrine reporter mice assessed by flow cytometry. (F) Identification of Citrine + cells as stromal cells (CD41 − CD45 − ) in Citrine reporter mice (Citrine +/+ ) by flow cytometry. Panels A-D used a polyclonal goat anti-mouse IL-33 antibody. FL, full length; IF, immunofluorescence; KO, knockout; mIL, mouse interleukin; SSC-A, side scatter.
    Polyclonal Goat, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/polyclonal goat/product/R&D Systems
    Average 94 stars, based on 1 article reviews
    polyclonal goat - by Bioz Stars, 2026-05
    94/100 stars
      Buy from Supplier

    94
    R&D Systems goat polyclonal anti il 33 r d systems cat
    <t>IL-33</t> <t>is</t> not expressed by circulating platelets or MKs. (A-B) Representative immunofluorescence images showing nonspecific IL-33 staining in bone marrow (BM)–derived MKs enriched on BSA gradient (A) and platelet-rich plasma (PRP) (B) from WT and IL-33KO mice. (C) Flow-cytometric detection of IL-33 nonspecific signal in blood platelets from WT and IL-33KO mice (PRP), using an isotype control as a negative reference. (D) Western blot analysis of IL-33 expression in platelets and MK-enriched BM cells, with total lung lysates from WT and IL-33 KO mice used as positive and negative controls, respectively. Following quantification, an equal amount of protein (20 μg) was loaded in each lane. (E) IL-33 promoter activity in total BM cells, blood platelets, and BM MK from IL-33–Citrine reporter mice assessed by flow cytometry. (F) Identification of Citrine + cells as stromal cells (CD41 − CD45 − ) in Citrine reporter mice (Citrine +/+ ) by flow cytometry. Panels A-D used a polyclonal goat anti-mouse IL-33 antibody. FL, full length; IF, immunofluorescence; KO, knockout; mIL, mouse interleukin; SSC-A, side scatter.
    Goat Polyclonal Anti Il 33 R D Systems Cat, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/goat polyclonal anti il 33 r d systems cat/product/R&D Systems
    Average 94 stars, based on 1 article reviews
    goat polyclonal anti il 33 r d systems cat - by Bioz Stars, 2026-05
    94/100 stars
      Buy from Supplier

    94
    R&D Systems goat polyclonal
    <t>IL-33</t> <t>is</t> not expressed by circulating platelets or MKs. (A-B) Representative immunofluorescence images showing nonspecific IL-33 staining in bone marrow (BM)–derived MKs enriched on BSA gradient (A) and platelet-rich plasma (PRP) (B) from WT and IL-33KO mice. (C) Flow-cytometric detection of IL-33 nonspecific signal in blood platelets from WT and IL-33KO mice (PRP), using an isotype control as a negative reference. (D) Western blot analysis of IL-33 expression in platelets and MK-enriched BM cells, with total lung lysates from WT and IL-33 KO mice used as positive and negative controls, respectively. Following quantification, an equal amount of protein (20 μg) was loaded in each lane. (E) IL-33 promoter activity in total BM cells, blood platelets, and BM MK from IL-33–Citrine reporter mice assessed by flow cytometry. (F) Identification of Citrine + cells as stromal cells (CD41 − CD45 − ) in Citrine reporter mice (Citrine +/+ ) by flow cytometry. Panels A-D used a polyclonal goat anti-mouse IL-33 antibody. FL, full length; IF, immunofluorescence; KO, knockout; mIL, mouse interleukin; SSC-A, side scatter.
    Goat Polyclonal, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/goat polyclonal/product/R&D Systems
    Average 94 stars, based on 1 article reviews
    goat polyclonal - by Bioz Stars, 2026-05
    94/100 stars
      Buy from Supplier

    99
    R&D Systems goat anti il 33 polyclonal r d systems
    <t>IL-33</t> <t>is</t> not expressed by circulating platelets or MKs. (A-B) Representative immunofluorescence images showing nonspecific IL-33 staining in bone marrow (BM)–derived MKs enriched on BSA gradient (A) and platelet-rich plasma (PRP) (B) from WT and IL-33KO mice. (C) Flow-cytometric detection of IL-33 nonspecific signal in blood platelets from WT and IL-33KO mice (PRP), using an isotype control as a negative reference. (D) Western blot analysis of IL-33 expression in platelets and MK-enriched BM cells, with total lung lysates from WT and IL-33 KO mice used as positive and negative controls, respectively. Following quantification, an equal amount of protein (20 μg) was loaded in each lane. (E) IL-33 promoter activity in total BM cells, blood platelets, and BM MK from IL-33–Citrine reporter mice assessed by flow cytometry. (F) Identification of Citrine + cells as stromal cells (CD41 − CD45 − ) in Citrine reporter mice (Citrine +/+ ) by flow cytometry. Panels A-D used a polyclonal goat anti-mouse IL-33 antibody. FL, full length; IF, immunofluorescence; KO, knockout; mIL, mouse interleukin; SSC-A, side scatter.
    Goat Anti Il 33 Polyclonal R D Systems, supplied by R&D Systems, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/goat anti il 33 polyclonal r d systems/product/R&D Systems
    Average 99 stars, based on 1 article reviews
    goat anti il 33 polyclonal r d systems - by Bioz Stars, 2026-05
    99/100 stars
      Buy from Supplier

    94
    R&D Systems goat anti mouse il 33 affinity purified polyclonal antibody
    <t>IL-33</t> <t>is</t> not expressed by circulating platelets or MKs. (A-B) Representative immunofluorescence images showing nonspecific IL-33 staining in bone marrow (BM)–derived MKs enriched on BSA gradient (A) and platelet-rich plasma (PRP) (B) from WT and IL-33KO mice. (C) Flow-cytometric detection of IL-33 nonspecific signal in blood platelets from WT and IL-33KO mice (PRP), using an isotype control as a negative reference. (D) Western blot analysis of IL-33 expression in platelets and MK-enriched BM cells, with total lung lysates from WT and IL-33 KO mice used as positive and negative controls, respectively. Following quantification, an equal amount of protein (20 μg) was loaded in each lane. (E) IL-33 promoter activity in total BM cells, blood platelets, and BM MK from IL-33–Citrine reporter mice assessed by flow cytometry. (F) Identification of Citrine + cells as stromal cells (CD41 − CD45 − ) in Citrine reporter mice (Citrine +/+ ) by flow cytometry. Panels A-D used a polyclonal goat anti-mouse IL-33 antibody. FL, full length; IF, immunofluorescence; KO, knockout; mIL, mouse interleukin; SSC-A, side scatter.
    Goat Anti Mouse Il 33 Affinity Purified Polyclonal Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/goat anti mouse il 33 affinity purified polyclonal antibody/product/R&D Systems
    Average 94 stars, based on 1 article reviews
    goat anti mouse il 33 affinity purified polyclonal antibody - by Bioz Stars, 2026-05
    94/100 stars
      Buy from Supplier

    Image Search Results


    IL-33 is not expressed by circulating platelets or MKs. (A-B) Representative immunofluorescence images showing nonspecific IL-33 staining in bone marrow (BM)–derived MKs enriched on BSA gradient (A) and platelet-rich plasma (PRP) (B) from WT and IL-33KO mice. (C) Flow-cytometric detection of IL-33 nonspecific signal in blood platelets from WT and IL-33KO mice (PRP), using an isotype control as a negative reference. (D) Western blot analysis of IL-33 expression in platelets and MK-enriched BM cells, with total lung lysates from WT and IL-33 KO mice used as positive and negative controls, respectively. Following quantification, an equal amount of protein (20 μg) was loaded in each lane. (E) IL-33 promoter activity in total BM cells, blood platelets, and BM MK from IL-33–Citrine reporter mice assessed by flow cytometry. (F) Identification of Citrine + cells as stromal cells (CD41 − CD45 − ) in Citrine reporter mice (Citrine +/+ ) by flow cytometry. Panels A-D used a polyclonal goat anti-mouse IL-33 antibody. FL, full length; IF, immunofluorescence; KO, knockout; mIL, mouse interleukin; SSC-A, side scatter.

    Journal: Blood Advances

    Article Title: The alarmin interleukin-33 modulates platelet proteome, function, and biogenesis

    doi: 10.1182/bloodadvances.2025018363

    Figure Lengend Snippet: IL-33 is not expressed by circulating platelets or MKs. (A-B) Representative immunofluorescence images showing nonspecific IL-33 staining in bone marrow (BM)–derived MKs enriched on BSA gradient (A) and platelet-rich plasma (PRP) (B) from WT and IL-33KO mice. (C) Flow-cytometric detection of IL-33 nonspecific signal in blood platelets from WT and IL-33KO mice (PRP), using an isotype control as a negative reference. (D) Western blot analysis of IL-33 expression in platelets and MK-enriched BM cells, with total lung lysates from WT and IL-33 KO mice used as positive and negative controls, respectively. Following quantification, an equal amount of protein (20 μg) was loaded in each lane. (E) IL-33 promoter activity in total BM cells, blood platelets, and BM MK from IL-33–Citrine reporter mice assessed by flow cytometry. (F) Identification of Citrine + cells as stromal cells (CD41 − CD45 − ) in Citrine reporter mice (Citrine +/+ ) by flow cytometry. Panels A-D used a polyclonal goat anti-mouse IL-33 antibody. FL, full length; IF, immunofluorescence; KO, knockout; mIL, mouse interleukin; SSC-A, side scatter.

    Article Snippet: However, IL-33 mRNA and protein have not been detected in previous platelet transcriptomic or proteomic studies., To resolve these discrepancies, we performed analyses with a polyclonal goat anti-mouse IL-33 antibody (R&D Systems, catalog no. AF3626) that has been validated for immunofluorescence, flow cytometry, and western blot analyses in previous studies , including several studies by our team., , , IL-33 is a nuclear cytokine and the Ab AF3626 stains the nucleus of IL-33 producing cells in WT mice but not in IL-33KO mice.

    Techniques: Immunofluorescence, Staining, Derivative Assay, Clinical Proteomics, Control, Western Blot, Expressing, Activity Assay, Flow Cytometry, Knock-Out

    IL-33 deficiency alters the platelet proteome. (A) Proteomic profiling of sorted platelets from WT and IL-33KO mice. (B) Volcano plot comparing IL-33KO and WT platelet proteomes. The x-axis shows log fold change (IL-33KO/WT), and the y-axis shows −log( P -value). Proteins upregulated in IL-33KO platelets are highlighted in blue; downregulated proteins in gray. (C) Number of proteins detected and significantly altered ( P < .03, fold change > 0.2). (D,F) Gene Ontology (GO) analysis of enriched biological processes among upregulated (D) and downregulated (F) proteins ( https://geneontology.org ). (E,G) Heat maps of the top 20 most abundant upregulated (E) and downregulated (G) proteins. Data were obtained from n = 5 mice per group. KO, knockout. Figure created with biorender.com . Blanchard L. (2026) https://BioRender.com/b78qj95 .

    Journal: Blood Advances

    Article Title: The alarmin interleukin-33 modulates platelet proteome, function, and biogenesis

    doi: 10.1182/bloodadvances.2025018363

    Figure Lengend Snippet: IL-33 deficiency alters the platelet proteome. (A) Proteomic profiling of sorted platelets from WT and IL-33KO mice. (B) Volcano plot comparing IL-33KO and WT platelet proteomes. The x-axis shows log fold change (IL-33KO/WT), and the y-axis shows −log( P -value). Proteins upregulated in IL-33KO platelets are highlighted in blue; downregulated proteins in gray. (C) Number of proteins detected and significantly altered ( P < .03, fold change > 0.2). (D,F) Gene Ontology (GO) analysis of enriched biological processes among upregulated (D) and downregulated (F) proteins ( https://geneontology.org ). (E,G) Heat maps of the top 20 most abundant upregulated (E) and downregulated (G) proteins. Data were obtained from n = 5 mice per group. KO, knockout. Figure created with biorender.com . Blanchard L. (2026) https://BioRender.com/b78qj95 .

    Article Snippet: However, IL-33 mRNA and protein have not been detected in previous platelet transcriptomic or proteomic studies., To resolve these discrepancies, we performed analyses with a polyclonal goat anti-mouse IL-33 antibody (R&D Systems, catalog no. AF3626) that has been validated for immunofluorescence, flow cytometry, and western blot analyses in previous studies , including several studies by our team., , , IL-33 is a nuclear cytokine and the Ab AF3626 stains the nucleus of IL-33 producing cells in WT mice but not in IL-33KO mice.

    Techniques: Knock-Out

    IL-33 deficiency impairs platelets adhesion to ECM components. (A) Schematic and (B) analysis of platelet adhesion assays to soluble fibrinogen, with or without ADP (1μM), assessed by flow cytometry. PRP from WT and IL-33 KO mice was analyzed, and results are expressed as a ratio relative to the WT mean. Data were obtained from n = 11 mice per group across 3 independent experiments. (C) Schematic of platelet spreading assays on fixed substrates, analyzed by immunofluorescence in WT and IL-33 KO platelets. Representative images and quantitative analyses of adherent and spreading PRP from WT or IL-33 KO mice on (D) fibrinogen, (E) podoplanin, and (F) laminin at 5 and 15 minutes following ADP (1μM) stimulation. Platelets were stained with CD41-APC. Data were obtained from n = 11 mice per group across 3 independent experiments, except for the laminin spreading assay, which was performed on n = 5 mice in a single experiment. (G-H) Platelet spreading assays without ADP stimulation on fibrinogen (G) and podoplanin (H) at 5 and 15 minutes (n = 7 mice per group per experiment). Statistical analyses were performed using t tests (D-F) and 2-way analysis of variance (ANOVA) with Sidak multiple comparisons test (B). Scale bar, 20 μm. Statistical analysis was conducted using t tests; # P < .05; ## P < .01; ### P < .001; #### P < .0001. IF, immunofluorescence. Figure created with biorender.com . Blanchard L. (2026) https://BioRender.com/z523pur .

    Journal: Blood Advances

    Article Title: The alarmin interleukin-33 modulates platelet proteome, function, and biogenesis

    doi: 10.1182/bloodadvances.2025018363

    Figure Lengend Snippet: IL-33 deficiency impairs platelets adhesion to ECM components. (A) Schematic and (B) analysis of platelet adhesion assays to soluble fibrinogen, with or without ADP (1μM), assessed by flow cytometry. PRP from WT and IL-33 KO mice was analyzed, and results are expressed as a ratio relative to the WT mean. Data were obtained from n = 11 mice per group across 3 independent experiments. (C) Schematic of platelet spreading assays on fixed substrates, analyzed by immunofluorescence in WT and IL-33 KO platelets. Representative images and quantitative analyses of adherent and spreading PRP from WT or IL-33 KO mice on (D) fibrinogen, (E) podoplanin, and (F) laminin at 5 and 15 minutes following ADP (1μM) stimulation. Platelets were stained with CD41-APC. Data were obtained from n = 11 mice per group across 3 independent experiments, except for the laminin spreading assay, which was performed on n = 5 mice in a single experiment. (G-H) Platelet spreading assays without ADP stimulation on fibrinogen (G) and podoplanin (H) at 5 and 15 minutes (n = 7 mice per group per experiment). Statistical analyses were performed using t tests (D-F) and 2-way analysis of variance (ANOVA) with Sidak multiple comparisons test (B). Scale bar, 20 μm. Statistical analysis was conducted using t tests; # P < .05; ## P < .01; ### P < .001; #### P < .0001. IF, immunofluorescence. Figure created with biorender.com . Blanchard L. (2026) https://BioRender.com/z523pur .

    Article Snippet: However, IL-33 mRNA and protein have not been detected in previous platelet transcriptomic or proteomic studies., To resolve these discrepancies, we performed analyses with a polyclonal goat anti-mouse IL-33 antibody (R&D Systems, catalog no. AF3626) that has been validated for immunofluorescence, flow cytometry, and western blot analyses in previous studies , including several studies by our team., , , IL-33 is a nuclear cytokine and the Ab AF3626 stains the nucleus of IL-33 producing cells in WT mice but not in IL-33KO mice.

    Techniques: Flow Cytometry, Immunofluorescence, Staining

    IL-33 deficiency reduces thrombus formation under high shear stress. (A) Schematic representation of the thrombus formation assay on collagen during arterial flow of whole blood from WT or IL-33 KO mice. (B) Representative images and quantitative analysis of thrombus volume, expressed as a percentage relative to the WT mean, formed on collagen under physiological arterial shear rate (1500 s ˗1 ) using whole blood from WT or IL-33 KO mice. (C) Representative images and quantitative analysis of thrombus volume, expressed as a percentage relative to the WT mean, formed on collagen under pathological arterial shear rate (3000 s ˗1 ) using whole blood from WT or IL-33 KO mice. Data are representative of 3 independent experiments (n = 4-5 mice/group). Statistical analysis was performed using 2-way ANOVA with Sidak multiple comparisons test, # P < .05. Investigators were blinded to genotype during the thrombus formation assay. Figure created with biorender.com . Blanchard L. (2026) https://BioRender.com/tt7i113 .

    Journal: Blood Advances

    Article Title: The alarmin interleukin-33 modulates platelet proteome, function, and biogenesis

    doi: 10.1182/bloodadvances.2025018363

    Figure Lengend Snippet: IL-33 deficiency reduces thrombus formation under high shear stress. (A) Schematic representation of the thrombus formation assay on collagen during arterial flow of whole blood from WT or IL-33 KO mice. (B) Representative images and quantitative analysis of thrombus volume, expressed as a percentage relative to the WT mean, formed on collagen under physiological arterial shear rate (1500 s ˗1 ) using whole blood from WT or IL-33 KO mice. (C) Representative images and quantitative analysis of thrombus volume, expressed as a percentage relative to the WT mean, formed on collagen under pathological arterial shear rate (3000 s ˗1 ) using whole blood from WT or IL-33 KO mice. Data are representative of 3 independent experiments (n = 4-5 mice/group). Statistical analysis was performed using 2-way ANOVA with Sidak multiple comparisons test, # P < .05. Investigators were blinded to genotype during the thrombus formation assay. Figure created with biorender.com . Blanchard L. (2026) https://BioRender.com/tt7i113 .

    Article Snippet: However, IL-33 mRNA and protein have not been detected in previous platelet transcriptomic or proteomic studies., To resolve these discrepancies, we performed analyses with a polyclonal goat anti-mouse IL-33 antibody (R&D Systems, catalog no. AF3626) that has been validated for immunofluorescence, flow cytometry, and western blot analyses in previous studies , including several studies by our team., , , IL-33 is a nuclear cytokine and the Ab AF3626 stains the nucleus of IL-33 producing cells in WT mice but not in IL-33KO mice.

    Techniques: Shear, Tube Formation Assay

    IL-33 treatment in vivo modifies platelet morphology and activation, expands the MK-biased LT-HSC pool, and enhances platelet release within lung capillaries. (A) Schematic overview of the IL-33 treatment protocol: WT mice received 3 intranasal doses of recombinant human IL-33 or PBS. (B) Flow cytometry analysis of platelet morphology in WT mice following IL-33 or PBS treatment. (C) Quantification of platelet counts by flow cytometry in IL-33- or PBS-treated WT mice. Data are from n = 14 mice per group, collected across 3 independent experiments. (D) Flow cytometry assessment of platelet degranulation, measuring alpha granule (P-selectin) and dense granule (CD63) expression after IL-33 or PBS administration. (E) Plasma levels of sCD40L, measured by ELISA in IL-33–treated or PBS-treated WT mice. (D-E) Data are from n = 8 to 9 mice per group, collected across 2 independent experiments. (F) Quantification of BM LT-HSC, separated into CD41 ˗ (canonical) and CD41 + (MK-biased) populations, shown as a percentage of LSK cells. Data are obtained from n = 22 mice per group, collected across 5 independent experiments. (G) Lung intravital microscopy was performed in PF4-mTmG mice treated with IL-33 or PBS, 24 hours after the first (IL-33 1×) or third (IL-33 3×) administration to assess MKs/proplatelets generating platelets. (H) Representative time-lapse intravital lung microscopy images showing PF4 + small proplatelets and large proplatelet/MK structures releasing platelets within pulmonary capillaries. Scale bar, 50 μm. (I-J) Quantification of proplatelet structures producing platelets per hour per ROI in the lung, categorized as small (<200 platelet volume equivalent), medium (200-1000 platelets), and large (>1000 platelets). (K) Total platelet release per hour across the entire lung. Statistical analysis was performed using t test; # P < .05, ## P < .01. A total of n = 5 to 21 videos were analyzed, collected from 3 to 11 mice per group across 5 independent experiments. ns, not significant. Figure created with biorender.com . Blanchard L. (2026) https://BioRender.com/qdgtyov .

    Journal: Blood Advances

    Article Title: The alarmin interleukin-33 modulates platelet proteome, function, and biogenesis

    doi: 10.1182/bloodadvances.2025018363

    Figure Lengend Snippet: IL-33 treatment in vivo modifies platelet morphology and activation, expands the MK-biased LT-HSC pool, and enhances platelet release within lung capillaries. (A) Schematic overview of the IL-33 treatment protocol: WT mice received 3 intranasal doses of recombinant human IL-33 or PBS. (B) Flow cytometry analysis of platelet morphology in WT mice following IL-33 or PBS treatment. (C) Quantification of platelet counts by flow cytometry in IL-33- or PBS-treated WT mice. Data are from n = 14 mice per group, collected across 3 independent experiments. (D) Flow cytometry assessment of platelet degranulation, measuring alpha granule (P-selectin) and dense granule (CD63) expression after IL-33 or PBS administration. (E) Plasma levels of sCD40L, measured by ELISA in IL-33–treated or PBS-treated WT mice. (D-E) Data are from n = 8 to 9 mice per group, collected across 2 independent experiments. (F) Quantification of BM LT-HSC, separated into CD41 ˗ (canonical) and CD41 + (MK-biased) populations, shown as a percentage of LSK cells. Data are obtained from n = 22 mice per group, collected across 5 independent experiments. (G) Lung intravital microscopy was performed in PF4-mTmG mice treated with IL-33 or PBS, 24 hours after the first (IL-33 1×) or third (IL-33 3×) administration to assess MKs/proplatelets generating platelets. (H) Representative time-lapse intravital lung microscopy images showing PF4 + small proplatelets and large proplatelet/MK structures releasing platelets within pulmonary capillaries. Scale bar, 50 μm. (I-J) Quantification of proplatelet structures producing platelets per hour per ROI in the lung, categorized as small (<200 platelet volume equivalent), medium (200-1000 platelets), and large (>1000 platelets). (K) Total platelet release per hour across the entire lung. Statistical analysis was performed using t test; # P < .05, ## P < .01. A total of n = 5 to 21 videos were analyzed, collected from 3 to 11 mice per group across 5 independent experiments. ns, not significant. Figure created with biorender.com . Blanchard L. (2026) https://BioRender.com/qdgtyov .

    Article Snippet: However, IL-33 mRNA and protein have not been detected in previous platelet transcriptomic or proteomic studies., To resolve these discrepancies, we performed analyses with a polyclonal goat anti-mouse IL-33 antibody (R&D Systems, catalog no. AF3626) that has been validated for immunofluorescence, flow cytometry, and western blot analyses in previous studies , including several studies by our team., , , IL-33 is a nuclear cytokine and the Ab AF3626 stains the nucleus of IL-33 producing cells in WT mice but not in IL-33KO mice.

    Techniques: In Vivo, Activation Assay, Recombinant, Flow Cytometry, Expressing, Clinical Proteomics, Enzyme-linked Immunosorbent Assay, Intravital Microscopy, Microscopy

    IL-33 in vivo treatment alters platelet proteome, modulating inflammatory and coagulation-related pathways. (A) Proteomic profiling of sorted platelets from WT mice treated with PBS or recombinant (rIL-33). (B) Volcano plot comparing human rIL-33 and PBS-treated mice platelet proteomes. The x-axis shows log fold change (IL-33KO/WT), and the y-axis shows ˗log( P -value). Proteins upregulated in IL-33 treated mice platelets are highlighted in orange; downregulated proteins in gray. (C) Number of proteins detected and significantly altered ( P < .03, fold change > 0.2). (D,F) Gene Ontology (GO) analysis of enriched biological processes among upregulated (D) and downregulated (F) proteins ( https://geneontology.org ). (E,G) Heat maps of the top 20 most abundant upregulated (E) and downregulated (G) proteins. Data represent n = 10 mice per group, collected from 2 independent experiments. Figure created with biorender.com . Blanchard L. (2026) https://BioRender.com/og48c3y .

    Journal: Blood Advances

    Article Title: The alarmin interleukin-33 modulates platelet proteome, function, and biogenesis

    doi: 10.1182/bloodadvances.2025018363

    Figure Lengend Snippet: IL-33 in vivo treatment alters platelet proteome, modulating inflammatory and coagulation-related pathways. (A) Proteomic profiling of sorted platelets from WT mice treated with PBS or recombinant (rIL-33). (B) Volcano plot comparing human rIL-33 and PBS-treated mice platelet proteomes. The x-axis shows log fold change (IL-33KO/WT), and the y-axis shows ˗log( P -value). Proteins upregulated in IL-33 treated mice platelets are highlighted in orange; downregulated proteins in gray. (C) Number of proteins detected and significantly altered ( P < .03, fold change > 0.2). (D,F) Gene Ontology (GO) analysis of enriched biological processes among upregulated (D) and downregulated (F) proteins ( https://geneontology.org ). (E,G) Heat maps of the top 20 most abundant upregulated (E) and downregulated (G) proteins. Data represent n = 10 mice per group, collected from 2 independent experiments. Figure created with biorender.com . Blanchard L. (2026) https://BioRender.com/og48c3y .

    Article Snippet: However, IL-33 mRNA and protein have not been detected in previous platelet transcriptomic or proteomic studies., To resolve these discrepancies, we performed analyses with a polyclonal goat anti-mouse IL-33 antibody (R&D Systems, catalog no. AF3626) that has been validated for immunofluorescence, flow cytometry, and western blot analyses in previous studies , including several studies by our team., , , IL-33 is a nuclear cytokine and the Ab AF3626 stains the nucleus of IL-33 producing cells in WT mice but not in IL-33KO mice.

    Techniques: In Vivo, Coagulation, Recombinant